Charles Schwab Investment Management Inc. Purchases 99,574 Shares of Option Care Health, Inc. (NASDAQ:OPCH)

Charles Schwab Investment Management Inc. increased its position in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 4.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,609,705 shares of the company’s stock after buying an additional 99,574 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Option Care Health were worth $91,209,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of OPCH. Wealthspire Advisors LLC bought a new position in Option Care Health in the first quarter valued at approximately $206,000. Geneva Capital Management LLC grew its stake in Option Care Health by 5.1% in the first quarter. Geneva Capital Management LLC now owns 781,625 shares of the company’s stock valued at $27,318,000 after purchasing an additional 38,105 shares in the last quarter. Lindenwold Advisors INC bought a new position in Option Care Health in the first quarter valued at approximately $308,000. US Bancorp DE grew its stake in Option Care Health by 5.0% in the first quarter. US Bancorp DE now owns 8,199 shares of the company’s stock valued at $287,000 after purchasing an additional 393 shares in the last quarter. Finally, Wealthquest Corp bought a new position in Option Care Health in the first quarter valued at approximately $66,000. 98.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on OPCH shares. UBS Group upgraded Option Care Health from a “neutral” rating to a “buy” rating and raised their price target for the company from $38.00 to $40.00 in a research note on Wednesday, April 30th. JMP Securities raised their price target on Option Care Health from $36.00 to $38.00 and gave the company a “market outperform” rating in a research note on Thursday, July 31st. Citigroup restated an “outperform” rating on shares of Option Care Health in a research note on Thursday, July 31st. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $38.00 price objective on shares of Option Care Health in a research report on Thursday, July 10th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $35.75.

Option Care Health Stock Performance

NASDAQ:OPCH opened at $28.54 on Wednesday. The stock has a market cap of $4.63 billion, a P/E ratio of 22.83, a PEG ratio of 1.76 and a beta of 0.79. The stock has a 50 day simple moving average of $30.50 and a 200 day simple moving average of $31.91. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.81. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $35.53.

Option Care Health (NASDAQ:OPCH) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.01. The business had revenue of $1.42 billion during the quarter, compared to analysts’ expectations of $1.35 billion. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%. The firm’s revenue for the quarter was up 15.4% compared to the same quarter last year. During the same period last year, the firm posted $0.30 EPS. Research analysts anticipate that Option Care Health, Inc. will post 1.22 earnings per share for the current year.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.